参考资料: [1] Lynparza and Imfinzi demonstrated strong clinical benefit and more than doubled median duration of response vs. chemotherapy in patients with mismatch repair proficient advanced or recurrent endometrial cancer. Retrieved March 18, 2024 from https://www.astrazeneca.com/media-centre/pres...
DOR 定义为从反应开始(当首次确定 CR 或 PR 时)到进展或死亡(以先发生者为准)的时间间隔。因为只有一小部分患者对积极治疗有反应,所以 DOR 的分析仅限于对反应者的描述性分析(例如,反应者的 Kaplan-Meier[KM] 曲线)。最近,利用与限制性平均生存时间(RMST)相关的成熟统计方法,Huang 等人公布了一种概念上简单...
Hu C, Wang MH, Wu C, et al. Comparison of Duration of Response vs Conventional Response Rates and Progression-Free Survival as Efficacy End Points in Simulated Immuno-oncology Clinical Trials. JAMA Netw Open. 2021 May 3;4...
. In MMR-proficient (pMMR) patients, ORRs were similar across all treatment arms, but the median DoR and proportion of patients in response at 18 months were higher with CP+D versus CP (10.6 vs 7.6 months and 37.4% ...